乌司奴单抗与阿达木单抗延迟应答者与早期应答者在生物制剂初治克罗恩病中具有相似结局
该研究为SEAVUE临床试验的事后分析,纳入373例中重度克罗恩病患者(乌司奴单抗187例,阿达木单抗186例),比较第8周早期应答者、第16周延迟应答者及无应答者的第56周临床缓解率。结果显示两种药物早期与延迟应答者的1年临床结局相似,延迟应答率整体较低(13.1%),延迟应答者第8周C反应蛋白较无应答者显著下降。
要点
- 乌司奴单抗和阿达木单抗延迟应答者与早期应答者的第56周临床缓解率无差异。
- SEAVUE项目中延迟临床应答率整体较低,为13.1%。
- 延迟应答者第8周C反应蛋白较无应答者显著下降,可能有助于鉴别。
核心结论
- 在中重度克罗恩病患者中,阿达木单抗和乌司奴单抗的早期与延迟应答者具有相似的1年临床结局。
- 最终延迟应答的患者在治疗最初8周内即可观察到生物标志物下降,可能有助于与无应答者区分。
研究设计与样本
- SEAVUE临床试验项目患者水平数据的事后分析。
- 共纳入373例参与者,其中乌司奴单抗治疗187例,阿达木单抗治疗186例。
- 第8周临床应答定义为克罗恩病活动指数(CDAI)评分较基线下降至少100分或CDAI评分<150,达此标准者为早期应答者,与延迟应答者(第8周无应答但第16周应答)及无应答者(第8周和第16周均无应答)进行比较。
- 主要结局为第56周临床缓解,定义为CDAI<150。
主要发现
- SEAVUE临床试验项目中延迟临床应答的总体发生率较低,为13.1%。
- 乌司奴单抗或阿达木单抗的早期应答者与延迟应答者之间,第56周临床缓解率无差异,次要结局亦无显著差异。
- 与无应答者相比,乌司奴单抗和阿达木单抗的延迟应答者第8周C反应蛋白显著下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Differences in 1-year outcomes among early and delayed responders have been demonstrated with some therapies in ulcerative colitis. However, it is unclear whether similar differences exist in patients with Crohn's disease (CD) treated with biologic therapies. METHODS: This was a post hoc analysis of patient-level data from the SEAVUE clinical trial program. Ustekinumab-treated and adalimumab-treated patients with clinical response at week 8, defined as a reduction in Crohn's Disease Activity Index (CDAI) score of at least 100 points from baseline or CDAI score <150, were deemed early responders and their outcomes were compared with delayed responders (week 8 nonresponders who subsequently responded at week 16) and nonresponders (no response at week 8 or 16). The primary outcome assessed was clinical remission at week 56, defined as CDAI <150. RESULTS: A total of 373 participants (187 treated with ustekinumab and 186 treated with adalimumab) were included in this analysis. The overall rate of delayed clinical response was low in the SEAVUE clinical trial program (13.1%). No differences were observed for week 56 clinical remission among early vs delayed responders to ustekinumab or adalimumab nor were there significant differences for secondary outcomes assessed. Delayed responders to ustekinumab and adalimumab had a significant decline in C-reactive protein by week 8 when compared with nonresponders. DISCUSSION: Among patients with moderate-to-severe CD, early and delayed responders to adalimumab and ustekinumab have similar 1-year clinical outcomes. Biomarker decline can be observed through the initial 8 weeks of therapy in patients who will eventually be delayed responders, which may help differentiate from nonresponders.
引用
- Narula N, Wong ECL, Dulai PS, et al. Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease. Am J Gastroenterol. 2024. PMID: 38235763. doi:10.14309/ajg.0000000000002654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。